Education
About Us
Working with TipRanks
Follow Us
Bolt Biotherapeutics (BOLT)
NASDAQ:BOLT
BOLT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.42 - $1.56
Previous CloseN/A
Volume72.19K
Average Volume (3M)114.67K
Market Cap
$16.92M
Enterprise Value-$11.63M
Total Cash (Recent Filing)-$13.63M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Mar 26, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding38,273,003
10 Day Avg. Volume87,562
30 Day Avg. Volume114,672
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.73
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.94
Enterprise Value/Ebitda0.16
Forecast
1Y Price Target
$1.50Price Target Upside240.91% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Bolt Biotherapeutics News
PremiumCompany Announcements
Bolt Biotherapeutics Announces Board Changes and Appointments
PremiumCompany Announcements
Bolt Biotherapeutics’ Restructuring Faces Potential Setbacks: A Closer Look
PremiumCompany Announcements
Bolt Biotherapeutics Reports Q3 2024 Financial Results
PremiumCompany Announcements
Bolt Biotherapeutics Announces Board Reshuffle and New Appointment
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsBOLT has made encouraging progress on their lead assets, BDC-3042 and BDC-4182.
Financial StabilityThe company had $84.4M in cash and equivalents as of September 30, 2024, and management expects it has a cash runway through mid-2026.
Bears Say
EarningsBolt reported 3Q24 revenue of $1.1M and EPS of ($0.40), compared to estimates of $1.7M and ($0.38), respectively.
---
Ownership Overview
11.18%
Insiders
3.86% Mutual Funds
41.67% Other Institutional Investors
40.03% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BOLT FAQ
What was Bolt Biotherapeutics’s price range in the past 12 months?
Bolt Biotherapeutics lowest stock price was $0.42 and its highest was $1.56 in the past 12 months.
What is Bolt Biotherapeutics’s market cap?
Bolt Biotherapeutics’s market cap is $16.92M.
When is Bolt Biotherapeutics’s upcoming earnings report date?
Bolt Biotherapeutics’s upcoming earnings report date is Mar 26, 2025 which is in 19 days.
How were Bolt Biotherapeutics’s earnings last quarter?
Bolt Biotherapeutics released its earnings results on Nov 12, 2024. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.34 by -$0.06.
Is Bolt Biotherapeutics overvalued?
According to Wall Street analysts Bolt Biotherapeutics’s price is currently Undervalued.
Does Bolt Biotherapeutics pay dividends?
Bolt Biotherapeutics does not currently pay dividends.
What is Bolt Biotherapeutics’s EPS estimate?
Bolt Biotherapeutics’s EPS estimate is -0.38.
How many shares outstanding does Bolt Biotherapeutics have?
Bolt Biotherapeutics has 38,273,003 shares outstanding.
What happened to Bolt Biotherapeutics’s price movement after its last earnings report?
Bolt Biotherapeutics reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.34. Following the earnings report the stock price went down -3.125%.
Which hedge fund is a major shareholder of Bolt Biotherapeutics?
Currently, no hedge funds are holding shares in BOLT
---
Company Description
Bolt Biotherapeutics
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
---
BOLT Stock 12 Month Forecast
Average Price Target
$1.50
▲(240.91% Upside)
Technical Analysis
Fate Therapeutics
―
Iovance Biotherapeutics
―
Affimed
―
Adaptimmune Therapeutics
―
Immatics
―
---